Sinopharm Group Co Ltd
XMUN:X2S
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Sinopharm Group Co Ltd (X2S) under the Base Case is 3.725 EUR per share.
Compared with the current market price of 1.932 EUR, the stock appears
Undervalued by 48% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Sinopharm Group Does
Sinopharm Group is one of China’s biggest drug distributors and pharmacy operators. It buys medicines, vaccines, medical devices, and healthcare products from manufacturers, then moves them through its own wholesale and retail network to hospitals, clinics, pharmacies, and other healthcare buyers. It also sells over-the-counter products and runs pharmacy stores under its own retail banners.
- Headquarters
- China CN
- Employees
- 94 910
- IPO date
- Sep 23, 2009
Sinopharm Group has no economic moat
Sinopharm Group Co Ltd lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Earnings Waterfall
Sinopharm Group Co Ltd
What is the Intrinsic Value of one X2S stock?
The intrinsic value for Sinopharm Group Co Ltd (X2S) under the Base Case is 3.725 EUR.
Is X2S stock undervalued or overvalued?
Compared with the current market price of 1.932 EUR, the stock appears Undervalued by 48% .
